Non-blocking PD-1 Antibodies for HIV and Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for HIV and cancer, such as antiviral therapy and immunotherapy, face challenges in effectively targeting and eliminating latent HIV reservoirs and exhausted tumor-specific CD8 T-cells due to persistent virus replication and regulatory receptor expression, particularly the PD-1/PD-L1 pathway.
Innovation Solution
Development of binding agents, including monoclonal antibodies and antibody drug conjugates, that specifically target PD-1, either as antagonists to restore T-cell function or agonists to modulate immune responses, with combinations of blocking and non-blocking antibodies to enhance immune cell rescue and apoptosis in HIV-infected cells and tumor tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antiviral drugs and immunotherapies are used to treat HIV and cancer, then disease control is achieved, but immune responses are not fully induced and T-cells become exhausted
Solution Approach 1:
The patent uses anti-PD-1 antibodies as intermediaries to block the interaction between PD-1 and PD-L1, preventing the transmission of inhibitory signals from PD-L1 to PD-1 on T-cells. This mediator approach restores T-cell function without directly activating T-cells, thereby controlling disease while avoiding T-cell exhaustion
Solution Approach 2:
The patent changes the binding parameters of PD-1 by introducing humanized antibodies with modified amino acid sequences that specifically bind to PD-1 with high affinity. This parameter change enables selective blockade of PD-1/PD-L1 interaction, restoring immune function while maintaining disease control
2Object-generated harmful factors
If blocking antibodies are used to restore T-cell function, then immune response is enhanced, but specificity and selectivity may be compromised
Solution Approach 1:
The patent applies local quality by designing antibodies that target specific epitopes on PD-1 with precise amino acid sequences. The humanized antibodies contain specifically engineered CDR regions that bind to particular sites on PD-1, ensuring localized and specific blockade of the PD-1/PD-L1 interaction while maintaining overall T-cell regulation
Solution Approach 2:
The patent creates humanized copies of antibody sequences that replicate the binding properties of original antibodies while improving specificity. The humanized IgG4 antibodies are engineered copies with optimized amino acid sequences that maintain high affinity for PD-1 while reducing off-target effects
3Productivity
If combination therapy with blocking and non-blocking antibodies is used, then synergistic effect is achieved, but treatment complexity increases
Solution Approach 1:
The patent segments the therapeutic approach by separating blocking and non-blocking antibody functions into distinct molecular entities with specific amino acid sequences. This segmentation allows each antibody to perform its specialized function while maintaining overall treatment simplicity through standardized administration protocols
Solution Approach 2:
The patent merges the functions of blocking and non-blocking antibodies into a coordinated combination therapy regimen. The humanized IgG4 antibodies are designed to work synergistically, with blocking antibodies preventing PD-L1 binding and non-blocking antibodies enhancing T-cell activation, thereby achieving enhanced therapeutic efficacy through functional integration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These agents effectively rescue exhausted T-cells, enhance proliferation and cytokine production, and induce apoptosis in PD-1 positive HIV-infected cells, potentially leading to sustained viral suppression and tumor control without lifelong antiviral therapy.
Implementation Method 1
humanized antibodies or fragments that specifically bind to human PD-1
Implementation Method 2
induce apoptosis in PD-1 high CD4 T-cells
Data Source
Figure 1A~1C
Figure 2
Figure 3A~3B
AI summary
This disclosure relates to binding agents with specificity for programmed cell death 1 (PD-1) and to methods for using the same to treat, prevent and / or ameliorate an infectious disease (e.g., human immunodeficiency virus (HIV)), cancer and / or autoimmunity. In addition, this disclosure identifies a novel binding patch ("P2") on PD-1 that is linked with a previously unidentified functional activity of PD-1 that is distinct from the interaction site involved with either the PD-L1 or PD-L2 ligands. Furthermore, we demonstrate that antibodies that interact with this region of PD-1 are able to act as antagonists of PD-1 and that this antagonism is further enhanced with the addition of antibodies that act through the blockade of the PD-1 / PD-L1/L2 interaction.